Race & Ethnicity In Clinical Trials: Breaking The Status Quo

By Kwame Marfo, Market Strategy and Innovation Lead, Clinical Development

Over the past few years, numerous instances of racial, ethnic, and socioeconomic disparities in care have bred growing resentment and pervasive mistrust of the American healthcare system, causing health equity to take center stage in the life sciences industry. Even though this issue is rife with difficulties, from access to care to institutional flaws in healthcare payment structures, one fundamental fact needs to be addressed before there can ever be meaningful progress.

People of color have been consistently underrepresented in clinical trials and have experienced worse outcomes and higher disease risk for decades. In fact, according to research by Komodo Health, 85% of oncology clinical trial participants over the last five years have been White. That’s a big problem.

By examining the historical lack of diversity in clinical trials, and the impact this has on patient outcomes, the author makes a case for more inclusive trial designs. Discover how researchers and healthcare providers can work towards breaking the status quo and promoting diversity in clinical trials by accessing the full article.